The pathogenesis of each disease is based on one or another typical pathological process: hypoxia, circulatory disorders, intoxication, neurotrophic disorders, etc. For a long period of time, drugs have been searched that could prevent the negative impact of these factors (Vertkin A.L. and et al., 2013). Today, the metabolic drug meldonium, which is part of the new drug RIPRONAT by World Medicine, meets these requirements to the greatest extent.
Meldonium has long been used in the pharmaceutical market of Ukraine and has earned trust among doctors and patients (Yermakovich I.I., 2011). Its use is indicated for diseases of the cardiovascular system, acute and chronic ischemic disorders of cerebral circulation, decreased ability to work, physical and psycho-emotional overstrain, as well as during the recovery period after cerebrovascular disorders, head injuries and encephalitis.
Such a wide range of indications makes meldonium a universal medicinal substance that is used in the treatment of various combined diseases (Zhitnikova L.M., 2012).
Meldonium RIPRONAT, produced by the European company World Medicine, deserves special attention on the Ukrainian pharmaceutical market. This drug is presented in three forms of release (solution in ampoules and capsules 250 mg and 500 mg), which allows the doctor to carry out gradual therapy and prescribe the drug both in acute conditions and during rehabilitation.
It is important to note that RIPRONAT in solution is convenient to use, since the frequency of application is only 1-2 times a day.
RIPRONAT is a drug produced in Europe, which contains the optimal ratio of price and quality.